Santhera Pharmaceuticals Holding AG

OTCPK:SPHD.F Stock Report

Market Cap: US$289.8m

Santhera Pharmaceuticals Holding Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of SPHD.F?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders363,1812.45%
Private Companies637,9334.3%
Institutions725,6554.89%
Public Companies1,414,6889.54%
General Public11,693,27778.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.3%.

Top Shareholders

Top 23 shareholders own 21.19% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.54%
Catalyst Pharmaceuticals, Inc.
1,414,688US$27.6m0%no data
4.3%
Santhera Pharmaceuticals (Schweiz) AG
637,933US$12.5m2.6%no data
2.85%
UBS Asset Management AG
422,290US$8.2m0%no data
1.5%
Joh. Berenberg, Gossler & Co. KG
222,165US$4.3m0%0.18%
1%
Dario Eklund
148,372US$2.9m0%no data
0.47%
Shabir Hasham
69,915US$1.4m0%no data
0.42%
Thomas Meier
62,501US$1.2m0%no data
0.25%
BlackRock, Inc.
36,793US$718.7k-1.09%no data
0.23%
Bradley Meyer
34,062US$665.3k0%no data
0.22%
Philipp Gutzwiller
32,805US$640.8k0%no data
0.13%
JPMorgan Chase & Co.
18,903US$369.2k-75.7%no data
0.071%
Dimensional Fund Advisors LP
10,545US$206.0k0%no data
0.043%
Oliver Kronenberg
6,380US$124.6k0%no data
0.031%
Geert-Jan van Daal
4,666US$91.1k0%no data
0.03%
Marc Schrader
4,480US$87.5k0%no data
0.029%
Swiss Life Asset Management AG
4,268US$83.4k0%no data
0.026%
Pictet Asset Management Limited
3,929US$76.8k0%no data
0.015%
AIF Alternativ Invest Finance AG
2,300US$44.9k0%0.13%
0.012%
State Street Global Advisors, Inc.
1,709US$33.4k1,310%no data
0.011%
Lombard Odier Asset Management (Switzerland) SA
1,662US$32.5k-87.6%no data
0.01%
CATAM Asset Management AG
1,500US$29.3k0%0.03%
0.0052%
LLB Asset Management AG
776US$15.2k0%no data
0.00088%
Deka Investment GmbH
130US$2.6k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 23:23
End of Day Share Price 2026/04/28 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Santhera Pharmaceuticals Holding AG is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard ParkesPiper Sandler Companies
null nullRBC Capital Markets
Christian GlennieStifel, Equities Research